GlassScriptPhysician profile
Andrew D Schriber
NPI 1801871173
$3,917.00
in general payments reported to CMS, 2019-2025
35 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $111 · 2021: $52.83 · 2022: $96.48 · 2023: $827 · 2024: $1,175 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,513.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,317.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $800.66 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $227.06 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $145.04 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $140.85 | 2023-2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $125.41 | 2023-2025 | |
| Amgen INC. | $114.46 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $111.29 | 2023-2025 | Aralast |
| Actelion Pharmaceuticals US, INC. | $97.16 | 2023-2025 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $78.40 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $69.27 | 2024-2025 | Lumryz |
| Insmed, INC. | $57.72 | 2020-2024 | Arikayce |
| Verona Pharma, INC. | $56.04 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $54.62 | 2025 | Tyvaso |
| Abbvie INC. | $53.72 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.42 | 2023-2025 | Winrevair, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.45 | 2023-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $38.37 | 2024-2025 | Xolair |
| Axsome Therapeutics, INC. | $37.93 | 2023-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $31.71 | 2019-2025 | |
| Baxter Healthcare | $22.80 | 2023 | Hillrom - Life 2000 Ventilation System |
| Viatris Specialty LLC | $22.40 | 2025 | Yupelri |
| Soleno Therapeutics, INC. | $21.93 | 2025 | Vykat Xr |
| W. L. Gore & Associates, INC. | $20.80 | 2021 | |
| Radius Health, INC. | $20.02 | 2025 | |
| Inspire Medical Systems, INC. | $19.08 | 2024 | Inspire |
| Lilly USA, LLC | $18.81 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $18.75 | 2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $17.83 | 2024 | Yupelri |
| Novo Nordisk INC | $16.61 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $15.60 | 2024 | Ultomiris |
| Shire North American Group INC | $14.19 | 2019 | |
| Electromed, INC. | $13.42 | 2023 | Smartvest |
| Paratek Pharmaceuticals, INC. | $13.10 | 2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schriber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.